US Broker Ratings

BioMarin Pharmaceutical Inc. (BMRN) Investor Outlook: Unveiling a 67.64% Potential Upside

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a leading biotechnology firm, is drawing significant attention from investors with an enticing potential upside of 67.64%. Despite a current trading price of $54.06, a..

Johnson & Johnson (JNJ) Stock Analysis: Exploring a Potential 14% Upside Amid Strong Revenue Growth

Johnson & Johnson (NYSE: JNJ), a titan in the healthcare sector, commands a substantial market capitalization of $532.77 billion, positioning it as a formidable player in the drug manufacturing industry...

United Therapeutics Corporation (UTHR) Stock Analysis: A 17.28% Upside Potential Beckons Investors

United Therapeutics Corporation (NASDAQ: UTHR), a prominent player in the healthcare sector, operates within the specialized niche of drug manufacturing. With a market capitalization of $23.98 billion, the company has..

Alcon Inc. (ALC) Stock Analysis: Eyeing a 41% Upside Potential Amid Robust Healthcare Growth

Alcon Inc. (NYSE: ALC), a leading player in the medical instruments and supplies industry, is making waves in the healthcare sector with its innovative eye care products. Headquartered in Geneva,..

Sanofi (SNY) Stock Analysis: 29% Potential Upside and a Robust Dividend Yield

Sanofi (SNY), the French pharmaceutical giant, continues to draw attention from investors with its diverse portfolio and promising market position. Operating in the healthcare sector, specifically within the general drug..

Bristol-Myers Squibb (BMY): Investor Outlook Reveals 12.75% Upside Potential Amidst Stable Growth

Bristol-Myers Squibb Company (NYSE: BMY) remains a compelling consideration for investors eyeing the healthcare sector, particularly in the drug manufacturing space. With a market cap of $114.68 billion, the company..

IQVIA Holdings, Inc. (IQV) Stock Analysis: Robust Growth Potential with a 27.92% Upside

IQVIA Holdings, Inc. (NYSE: IQV), a leader in the healthcare sector, is capturing the attention of savvy investors with its impressive growth trajectory and strong upside potential. With a market..

Takeda Pharmaceutical (TAK) Stock Analysis: Strong Buy Ratings and a 25.67% Upside Potential

Takeda Pharmaceutical Company Limited (NYSE: TAK), a stalwart in the healthcare sector, is one of the leading players in the specialty and generic drug manufacturing industry. Headquartered in Tokyo, Japan,..

Cardinal Health, Inc. (CAH) Stock Analysis: Strong Buy Ratings and 33.55% Potential Upside Propel Investor Interest

Cardinal Health, Inc. (NYSE: CAH), a leading player in the healthcare sector, operates across two main segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. With a market..

Elevance Health, Inc. (ELV) Stock Analysis: Exploring Growth Potential in the Healthcare Sector

Elevance Health, Inc. (NYSE: ELV), a prominent player in the healthcare plans industry, is commanding investor attention with a robust market cap of $82.1 billion. As a key provider of..

AstraZeneca PLC (AZN): Investor Outlook Reveals 22.39% Upside Potential and Strong Buy Ratings

AstraZeneca PLC (AZN) continues to draw investors’ attention with its robust position in the healthcare sector, specifically within the drug manufacturing industry. Based in the United Kingdom, the company is..

Natera, Inc. (NTRA) Stock Analysis: A 34% Upside Potential Amidst Rapid Revenue Growth

Natera, Inc. (NASDAQ: NTRA), a prominent player in the diagnostics and research industry, has caught the attention of investors with its robust revenue growth and substantial upside potential. As the..

Regeneron Pharmaceuticals, Inc. (REGN): Analyst Consensus and 22% Growth Potential

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), a leading name in the biotechnology sector, has been a focal point for investors eyeing significant growth potential. With a market capitalization of $74.95 billion..

Quest Diagnostics (DGX) Investor Outlook: Analyzing the 19% Potential Upside for Savvy Investors

As a leading player in the healthcare diagnostics sector, Quest Diagnostics Incorporated (NYSE: DGX) represents a compelling opportunity for investors looking to capitalize on the growing demand for diagnostic and..

Stryker Corporation (SYK) Stock Analysis: Exploring a 37% Upside Potential with Strong Buy Ratings

Stryker Corporation (NYSE: SYK) stands out as a compelling player in the healthcare sector, specifically within the medical devices industry. With a robust market capitalization of $109.33 billion, the company..

argenx SE (ARGX) Stock Analysis: Tapping Into a 32% Upside in the Booming Biotech Sector

argenx SE (NASDAQ: ARGX), a Netherlands-based biopharmaceutical company, is creating significant buzz in the healthcare sector, particularly within the biotechnology industry. With a robust market capitalization of $48.88 billion, argenx..

AbbVie Inc. (ABBV) Stock Analysis: Exploring a 25% Potential Upside Amid Robust Revenue Growth

AbbVie Inc. (NYSE: ABBV), a leading player in the healthcare sector, continues to capture investor attention with a robust market cap of $356.49 billion. This biopharmaceutical giant is renowned for..

Amgen Inc. (AMGN) Stock Analysis: Evaluating Growth Potential Amid Strong Analyst Ratings

Amgen Inc. (AMGN), a titan in the healthcare sector, stands out in the drug manufacturing industry with its robust pipeline of human therapeutics. With a market capitalization of $179.12 billion,..

Teva Pharmaceutical Industries (TEVA) Stock Analysis: Unlocking 12.71% Potential Upside

Teva Pharmaceutical Industries (NYSE: TEVA), a pivotal player in the healthcare sector, particularly within the specialty and generic drug manufacturing industry, has captured investor attention with a potential upside of..

UnitedHealth Group (UNH) Stock Analysis: Navigating the Healthcare Giant’s Growth and Dividend Potential

UnitedHealth Group Incorporated (NYSE: UNH), a leading player in the healthcare plans industry, continues to hold a firm grip on the market with a substantial market capitalization of $345.08 billion...

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds